CNS & Neurological Disorders - Drug Targets
Title:Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
Volume: 17 Issue: 3
Author(s): Hari S. Sharma*, Stephen D. Skaper and Aruna Sharma
Affiliation:
- International Experimental Central Nervous System Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, SE-75185 Uppsala,Sweden
Export Options
About this article
Cite this article as:
Sharma S. Hari *, Skaper D. Stephen and Sharma Aruna , Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018, CNS & Neurological Disorders - Drug Targets 2018; 17 (3) . https://dx.doi.org/10.2174/187152731703180619162802
DOI https://dx.doi.org/10.2174/187152731703180619162802 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beyond Rodent Models of Pain: Non-Human Primate Models for Evaluating Novel Analgesic Therapeutics and Elaborating Pain Mechanisms
CNS & Neurological Disorders - Drug Targets Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid
Current Medicinal Chemistry Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry The Risk That DSM 5 Will Exacerbate the SVP Mess in Forensic Psychiatry
Current Psychiatry Reviews Hydrops Fetalis and THE Parvovirus B-19
Current Pediatric Reviews Electroporation Advances in Large Animals
Current Gene Therapy Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway
Clinical Cancer Drugs Multitasking of Neuropeptide Y through the Lens of Motifs
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Anterior Labial Alveolar Bone Thickness after Orthodontic Retraction of Anterior Teeth
Current Dentistry Analgesic Drug Use Associated with Statin Prescription – A Cross- Sectional Study in Primary Care Settings
Current Drug Safety Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Fishing for Age-Related Visual System Mutants: Behavioral Screening of Retinal Degeneration Genes in Zebrafish
Current Aging Science